Esplora

European Partnership on Rare Diseases (ERDERA) (Phase 2)

European Commission

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: ...

• EU
• ATMP

Scadenza

15/09/2026, 00:00(34 gg)

Importo

91.300.000 €

Contributo

non specificato

Territorio

EU

Enhancing integrated research and healthcare in sub-Saharan Africa through digital innovation and Artificial Intelligence

European Commission

The action aims to strengthen clinical human capital base in R&I, enhance talent retention, knowledge sharing, accelerate integration of digital tools into health systems, and expand validated innovations in sub-Saharan Africa.

• In scadenza
• EU
• National governments
• Regional institutions
• Africa

Scadenza

02/09/2026, 00:00(21 gg)

Importo

2.250.000 €

Contributo

non specificato

Territorio

EU

Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers

European Commission

Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers

• EU
• Clinical Trials

Scadenza

15/09/2026, 00:00(34 gg)

Importo

8.000.000 €

Contributo

non specificato

Territorio

EU

HORIZON-JU-EDCTP3-2026-Dr Pascoal Mocumbi Prize

European Commission

Recognition prize under Horizon Europe for outstanding contributions to clinical development of products for poverty-related diseases and Africa-Europe partnerships in global health research.

• In scadenza
• EU
• Africa

Scadenza

02/09/2026, 00:00(21 gg)

Importo

50.000 €

Contributo

non specificato

Territorio

EU

Decode the Immunoscience of age-related diseases

European Commission

The action under this topic aims to elucidate the key biological determinants that drive healthy ageing and immune-mediated disease, with a particular focus on how age-associated immune system remodelling shapes these outcomes.

• EU
• Applicants
• consortium
• IHI

Scadenza

08/10/2026, 00:00(57 gg)

Importo

9.200.000 €

Contributo

non specificato

Territorio

EU

IA Resilience call reinforcing Europe's strenght in health

European Commission

• EU

Scadenza

16/09/2026, 00:00(35 gg)

Importo

20.000.000 €

Contributo

non specificato

Territorio

EU

Towards a European production of stable isotopes for novel nuclear medicine therapies (SAMIRA/ERVI)

European Commission

The project results are expected to contribute to the following outcomes: support for the development of EU production of stable isotopes that are essential for the manufacturing of radionuclides used in novel nuclear medicine therapies; strengthening of the resilience and security of the EU medical radioisotope supply chain by securing access to source materials, reducing dependence on third countries and enhancing industrial-scale production (including the sourcing of stable isotopes); leveraging of the knowledge and expertise of nuclear scientists, physicists and engineers in order to develop and optimise the processes for the EU-based production of stable isotopes, while contributing to Europe’s Beating Cancer Plan and implementing the Strategic Agenda for Medical Ionising Radiation Applications (SAMIRA).

• EU
• nuclear medicine

Scadenza

15/09/2026, 00:00(34 gg)

Importo

2.000.000 €

Contributo

non specificato

Territorio

EU